DBV Technologies and Stallergenes have entered into a strategic research partnership to develop immunotherapy treatments for respiratory allergies using DBV's skin patch, Viaskin.
The collaboration combines Stallergenes' know-how in respiratory allergies with DBV's Viaskin, a platform that grants epicutaneous desensitization.
The preclinical work will be conducted by DBV, up to proof-of-concept studies using Viaskin and Stallergenes' aeroallergens.
Stallergenes will finance DBV's research on the aeroallergens and will have development and commercialization rights.
DBV Technologies chairman and CEO Pierre-Henri Benhamou said that the agreement with Stallergenes is very much in line with the company's strategy to expand its Viaskin proprietary platform beyond food allergies.
"Both companies share a passion for innovation, and I strongly believe that the combination of our respective strengths will lead to best-in-class treatments for the benefit of patients," Benhamou added.
Stallergenes CEO Roberto Gradnik said, "Our expertise combined with DBV's new route of administration will give the opportunity to patients, especially young children, to benefit from a new innovative solution in allergen immunotherapy."
DBV and Stallergenes are expected to enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization in the upcoming months.
